Both are virucidal (protease inhihitors) added to the current not so satisfactory pegylated interferon and ribavirin treatment for Hepatitis C infection.
Hepatitis C tend to become chronic and in many the disease may progress to chronic hepatitis, cirrhosis of liver and liver cancer.
Vertex Pharmaceuticals producing telaprevir as incivek, set a wholesale price of $49,200 for a 12-week regimen, which works in combination with pegylated interferon and ribavirin; after which pegylated interferon and ribavirin are to be continued for as few as another 12 weeks.
Merck's boceprevir marked as Victrelis has a wholesale price of $1,100 per week, or between $26,400 and $48,400 for a course of treatment, depending on needed duration.
Telaprevir may have an edge over Boceprevir at present as regards the cost factor and shorter duration of treatment.
However, now at least two good drugs are available for use.